Brief: Adagene Announces Safebody Multi-Target Collaboration With Sanofi

Adagene

02/03/2022 12:32

March 2 (Reuters) - Adagene Inc  978y.F :
    * ADAGENE ANNOUNCES SAFEBODY® MULTI-TARGET COLLABORATION
WITH
SANOFI FOR NOVEL MASKED IMMUNO-ONCOLOGY ANTIBODY CANDIDATES
    * ADAGENE - CO TO BE RESPONSIBLE FOR EARLY STAGE RESEARCH
ACTIVITIES TO DEVELOP MASKED VERSIONS OF SANOFI CANDIDATE
ANTIBODIES, USING CO'S SAFEBODY TECHNOLOGY
    * ADAGENE INC - SANOFI WILL BE SOLELY RESPONSIBLE FOR LATER
STAGE
RESEARCH AND ALL CLINICAL, PRODUCT DEVELOPMENT AND
COMMERCIALIZATION ACTIVITIES
    * ADAGENE INC - SANOFI WILL MAKE AN UPFRONT PAYMENT OF $17.5
MILLION TO ADAGENE
    * ADAGENE - ELIGIBLE TO RECEIVE TOTAL POTENTIAL DEVELOPMENT,
REGULATORY, COMMERCIAL MILESTONE PAYMENTS OF UP TO $2.5 BILLION
FOR ADVANCEMENT OF CANDIDATES
    * ADAGENE INC - ELIGIBLE TO ALSO RECEIVE TIERED ROYALTIES ON
GLOBAL NET SALES OF APPROVED COLLABORATION PRODUCTS

Source text for Eikon:  ID:nGNX9lbyCt 
Further company coverage:  978y.F 

 ((reuters.briefs@thomsonreuters.com;))